Date: 2011-06-30
Type of information: Production agreement
Compound: manufacturing process for recombinant human Nerve Growth Factor (rhNGF)
Company: Scil Proteins (Germany) Anabasis Pharma (Italy)
Therapeutic area: Ophtalmological diseases
Type agreement: licensing
manufacturing
production
Action mechanism:
Disease: Eye diseases including neurotrophic keratitis, dry eye and glaucoma
Details: Scil Proteins has signed an agreement with Anabasis Pharma. Under the terms of this agreement Scil Proteins will license the microbial based manufacturing process for recombinant human Nerve Growth Factor (rhNGF) to Anabasis. Scil Proteins is responsible for the development of the production process, the respective technology transfer and holds an option for later GMP manufacturing at its facilities. Anabasis together with its parent company Dompé Group will develop rhNGF for use in eye diseases including neurotrophic keratitis, dry eye and glaucoma.
Financial terms: Scil Proteins will be eligible for milestone payments during development, together with license fees and royalties on sales.
Latest news:
